|
1）Mimori T, Imura Y, Nakashima R, et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19: 523-9
|
|
|
|
2）Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52: 1571-6
|
|
|
|
|
|
3）Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive ILD. Arthritis Rheum. 2009; 60: 2193-200
|
|
|
|
|
|
4）Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010; 49: 433-40
|
|
|
|
|
|
5）Nobutoh T, Kohda M, Doi Y, et al. An autopsy case of dermatomyositis with rapidly progressive diffuse alveolar damage. J Dermatol. 1998; 25: 32-6
|
|
|
|
|
6）Miyazaki E, Ando M, Muramatsu T. et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007; 26: 436-9
|
|
|
|
|
|
7）Ideura G, Hanaoka M, Koizumi T, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007; 101: 1406-11
|
|
|
|
|
|
8）Fujikawa K, Kawakami A, Kaji K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009; 38:263-7
|
|
|
|
|
|
9）Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49: 1713-9
|
|
|
|
|
|
10）Ikeda N, Takahashi K, Yamaguchi Y, et al. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011; 38: 973-9
|
|
|
|
|
|
11）Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011; 147: 391-8
|
|
|
|
|
|
12）Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105: 1380-87
|
|
|
|
|
|
13）Sato S, Kuwana M, Fujita T, et al. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2012; 22: 625-9
|
|
|
|
|
|
14）Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010; 11: 223
|
|
|
|
|
|
15）Chen F, Wang D, Shu X, et al. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012; 32: 3909-15
|
|
|
|
|
|
16）Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-MDA5 antibody. Arthritis Care Res (Hoboken). 2012; 64: 1602-10
|
|
|
|
|
|
17）Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011; 65: 25-34
|
|
|
|
|
|
18）Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012; 91: 220-8
|
|
|
|
|
|
19）Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-MDA5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013; 65: 1307-15
|
|
|
|
|
|
20）Betteridge Z, Tansley S, Gunawardena H, et al. Clinical phenotypes of caucasian adult and juvenile dermatomyositis patients with anti-MDA5 autoantibodies. Arthritis Rheum. 2012; 64: S715
|
|
|
|
|
|
21）Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013; 107: 745-52
|
|
|
|
|
|
22）Morita Y, Kuwagata S, Kato N, et al. 18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. Intern Med. 2012; 51: 1613-8
|
|
|
|
|
23）Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013; 23: 496-502
|
|
|
|
|
|
24）Muro Y, Sugiura K, Hoshino K, et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012; 51: 800-4
|
|
|
|
|
|
25）Kuwana M, Sato S, Shirai Y, et al. Initial predictors of poor survival in patients with dermatomyositis and interstitial lung disease. Arthritis Rheum. 2011; 63: S87
|
|
|
|
|
|
26）Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012; 51: 1563-70
|
|
|
|
|